Phio Pharmaceuticals Corp. (PHIO) Executive Compensation
Phio Pharmaceuticals Corp. (PHIO) is a publicly traded company on the Nasdaq, categorized under SIC 2834 (Pharmaceutical Preparations). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: PHIO
CIK: 1533040
Exchange: Nasdaq
SIC 2834: Pharmaceutical Preparations
Fiscal Year End: 12/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
Grant Thornton LLP
Auditor SinceSince 12/31/2025 12:00:00 AM
Lead Engagement PartnerAlexis Abate
Audit LocationPhiladelphia, Pennsylvania, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 8-K | 2026-10-13 | 2026-10-13 | FORM 8-K | 0001437749-26-032505 | View SEC Doc Filr Page |
| 4 | 2026-09-30 | 2026-09-28 | 4 Filing | 0001683168-26-007499 | View SEC Doc Filr Page |
| 4 | 2026-09-29 | 2026-09-28 | 4 Filing | 0001683168-26-007481 | View SEC Doc Filr Page |
| 4 | 2026-09-29 | 2026-09-28 | 4 Filing | 0001683168-26-007483 | View SEC Doc Filr Page |
| 4 | 2026-09-29 | 2026-09-28 | 4 Filing | 0001683168-26-007482 | View SEC Doc Filr Page |
| S-8 | 2026-09-28 | — | FORM S-8 | 0001437749-26-031367 | View SEC Doc Filr Page |
| 8-K | 2026-09-28 | 2026-09-28 | FORM 8-K | 0001437749-26-031337 | View SEC Doc Filr Page |
| 4 | 2026-09-25 | 2026-09-24 | 4 Filing | 0001683168-26-007432 | View SEC Doc Filr Page |
| 4 | 2026-09-23 | 2026-09-22 | 4 Filing | 0001683168-26-007321 | View SEC Doc Filr Page |
| 4 | 2026-09-16 | 2026-09-15 | 4 Filing | 0001683168-26-007192 | View SEC Doc Filr Page |
| 4 | 2026-09-15 | 2026-09-11 | 4 Filing | 0001683168-26-007158 | View SEC Doc Filr Page |
| 4 | 2026-09-15 | 2026-09-11 | 4 Filing | 0001683168-26-007159 | View SEC Doc Filr Page |
| 8-K | 2026-09-14 | 2026-09-14 | FORM 8-K | 0001437749-26-030236 | View SEC Doc Filr Page |
| 4 | 2026-08-20 | 2026-08-19 | 4 Filing | 0001683168-26-006620 | View SEC Doc Filr Page |
| 4 | 2026-08-19 | 2026-08-18 | 4 Filing | 0001683168-26-006592 | View SEC Doc Filr Page |
| ARS | 2026-08-14 | 2025-12-31 | ANNUAL REPORT | 0001683168-26-006475 | View SEC Doc Filr Page |
| DEFA14A | 2026-08-14 | — | ADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALS | 0001683168-26-006474 | View SEC Doc Filr Page |
| DEF 14A | 2026-08-14 | 2026-09-28 | FORM DEF 14A | 0001437749-26-027997 | View SEC Doc Filr Page |
| 8-K | 2026-08-06 | 2026-08-06 | FORM 8-K | 0001437749-26-026275 | View SEC Doc Filr Page |
| 10-Q | 2026-08-06 | 2026-06-30 | FORM 10-Q | 0001437749-26-026271 | View SEC Doc Filr Page |
| 3 | 2026-07-30 | 2026-07-20 | 3 Filing | 0001683168-26-005842 | View SEC Doc Filr Page |
| 8-K | 2026-07-21 | 2026-07-21 | FORM 8-K | 0001437749-26-023916 | View SEC Doc Filr Page |
| 4 | 2026-06-29 | 2026-06-26 | 4 Filing | 0001683168-26-005164 | View SEC Doc Filr Page |
| 10-Q | 2026-05-07 | 2026-03-31 | FORM 10-Q | 0001437749-26-015604 | View SEC Doc Filr Page |
| 8-K | 2026-05-07 | 2026-05-07 | FORM 8-K | 0001437749-26-015590 | View SEC Doc Filr Page |